Current Issue 2018  Archive 2017 
Biography
Biography

Editor-in-Chief of OBM Hepatology and Gastroenterology

Osamu Yokosuka is an Emeritus Professor of Chiba University, Japan. He graduated from Chiba University School of Medicine in 1975 then worked as a trainee under Professor K. Okuda in Chiba University Hospital till 1978. Dr. Yokosuka was a research fellow worked under Professor S. Scherlock and Professor B. H. Billing in Royal Free Hospital, London, UK from 1978 to 1980; under Professor M. Omata in Chiba University from 1980 to 1985; and under Dr. J Summers in Fox Chase Cancer Center, PA, USA in 1984. In 1985, he received a Degree of Doctor of Medical Science, and served as an Assistant Professor in Chiba University till 1994, then as Lecturer in Medicine till 2006 when he was appointed as Director and Professor of Medicine. From 2013 to 2015, he served as the Dean of Chiba University School of Medicine.

Dr. Yokosuka was the Secretary General of APASL (2008-2014). In 2016, he was elected as the President of APASL Tokyo, the President of 52nd Annual Meeting of Japan Society of Hepatology, and the President of Funabashi Central Hospital. Dr. Yokosuka’s research mainly focuses on Hepatitis and Hepatocellular Carcinoma. So far, he has published more than 700 original papers.

Biography

The Associate Editor of OBM Hepatology and Gastroenterology

Tatsuo Kanda received a medical degree in 1991 at Niigata University School of Medicine, Japan, and his PhD in 1999 at Chiba University Graduate School of Medicine, Japan. He had post-doctor training for 3 years under Prof. Ratna Ray and Prof. Ranjit Ray at Saint Louis University, St. Louis, MO, USA. In Dec. 2008, Tatsuo Kanda became a Tenure-track Associate Professor at Department of Medicine and Clinical Oncology, Chiba University, Graduate School of Medicine, Japan. In Feb. 2013, Tatsuo Kanda was nominated a permanent Associate Professor at Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Japan. In 2017, Tatsuo Kanda became an Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine. For ~25 years, he has focused his scientific interests on the topics related to liver diseases including acute liver failure, viral hepatitis and autoimmune liver diseases, and worked with Prof. Osamu Yokosuka. Tatsuo Kanda is also an expert for hepatitis A virus (HAV), HBV and HCV, and translation and replication of these viruses, and hepatocarcinogenesis. With his expertise in antiviral therapies and hepatitis virus research, Tatsuo Kanda also sees a lot of patients in clinical daily practice. Tatsuo Kanda has published more than 200 articles in peer-reviewed Journal.

Special Issue

Peril and Promise: The Present and Future of Kidney Transplantation

Submission Deadline: November 30, 2018 (Open)               Submit Now

Guest Editor

Steven Potter, MD, FACS
Transplant Program Director, Chair of Division of Transplantation, East Texas Medical Center, 1100 E. Lake St., Ste. 340, Tyler, TX 75701, USA
E-Mail: [email protected]
Research Interests: renal transplantation; pancreas transplantation; living kidney donation; transplant immunosuppression; urology; urologic oncology

About This Topic

This special issue aims to focus on trends and strategic efforts to increase deceased and living donor transplant volumes (for example, a manuscript about living donor paired exchange, living donor chains etc and articles about efforts to transplant more highly sensitized recipients in the United States (via changes in the Kidney Allocation System), some of the outcome and financial barriers that have led to a move away from desensitization protocols, and the efforts to increase the utilization of high KDPI deceased donor kidneys.

Admittedly, these are potentially too United States centric, as they involve regulatory, financial, and cultural approaches that may not be generalizable to other nations. We would like your thoughts on that.

We would also like to consider manuscripts on potential new immunosuppressive agents, outcomes data, and the critically important emergence of APOL1 as a prognostic indicator for assessment of both living donor and deceased donor transplants.